MannKind Corp (NASDAQ:MNKD)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.

Recs

0
Player Avatar modestus1 (< 20) Submitted: 8/13/2011 10:57:22 PM : Outperform Start Price: $2.91 MNKD Score: -52.07

drug speculation

Report this Post Reply

Featured Broker Partners


Advertisement